Arabic Arabic English English French French German German
dark

Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO Congress

Targovax ASA announces that the abstract “A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma” will be presented as an e-poster at the European Society for Medical Oncology congress by Dr Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

AlzeCure’s ACD856 Demonstrates Good Tolerability in Phase I Clinical Trial and is Approved for Additional Doses

Next Post

New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)

Related Posts
Total
0
Share